Form 4: Aurinia Pharmaceuticals Director Acquires Shares and Options
SEC Form 4 Filing
Director David R.W. Jayne acquired 12,135 restricted stock units and 18,641 stock options in Aurinia Pharmaceuticals.
Summary
- David R.W. Jayne, a director at Aurinia Pharmaceuticals, has reported a transaction involving the acquisition of company securities.
- On November 21, 2024, Jayne acquired 12,135 restricted stock units (RSUs), which are payable in common shares of the company.
- These RSUs will vest one year from the grant date.
- Additionally, Jayne acquired 18,641 stock options with an exercise price of $8.24 per share.
- These options also vest one year from the grant date and expire on November 21, 2034.
- Following these transactions, Jayne directly owns 56,499 common shares and 18,641 stock options.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction by a director, which is generally viewed positively as it indicates confidence in the company. However, it is not a major event that would significantly impact sentiment.
Positives
- The acquisition of shares and options by a director can be seen as a positive sign of confidence in the company's future prospects.
- The vesting period of one year for both the RSUs and options aligns the director's interests with the long-term performance of the company.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders such as directors or officers make transactions in the company's securities. It is a routine disclosure required by law to ensure transparency in the market.
Comparison to Industry Standards
- The vesting period of one year for both the RSUs and options is a common practice in the industry.
- The exercise price of $8.24 for the stock options is specific to Aurinia Pharmaceuticals and would need to be compared to the current market price of the stock to assess its value.
Stakeholder Impact
- The acquisition of shares and options by a director may be viewed positively by shareholders as it indicates confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 11/21/2024 | Date of the transaction where the director acquired restricted stock units and stock options. |
| 11/25/2024 | Date the form was signed by the reporting person. |
| 11/21/2034 | Expiration date of the stock options. |
Keywords
Aurinia Pharmaceuticals, Director, David R.W. Jayne, Stock Options, Restricted Stock Units, RSUs, Share Acquisition, Insider Trading, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.